Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection
Shopen et al., medRxiv, doi:10.1101/2022.01.29.22270090
https://c19early.org/shopen.html